SEC Form 4 · accession 0001179110-16-028545

Traws Pharma, Inc. · TRAW

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jul 26, 2016

Accepted (ET)

Aug 10, 2016 · 8:32 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001130598

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Aug 1, 2016	X	24,405	$4.10	A	24,415	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Subscription Rights (right to buy)^F1	$4.10	Jul 26, 2016	X	15	D	Jul 8, 2016	Jul 26, 2016	See Footnote	15	0	D
Warrants (right to buy)^F1,F2	$4.92	Aug 1, 2016	X	18,303	A	Jul 29, 2016	Jul 27, 2021	Common Stock	18,303	18,303	D

F1The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Onconova Therapeutics, Inc. (the "Company) to all holders of the Company's common stock. The subscription rights entitled each recipient thereof to purchase 1.5 units ("Units") for each share of stock owned. Each Unit consists of one share of the Company's common stock and 0.75 of a warrant, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $4.10. Shareholders could also subscribe for an additional allocation of Units, for which rights were not exercised. This allocation to shareholders was completed on August 1, 2016.
F2Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $4.92 from the date of issuance through July 27, 2021.